Effect of Supplemental Vitamin D and Calcium on Serum Sclerostin Levels

Overview

Journal Eur J Endocrinol

Publisher Oxford University Press

Specialty Endocrinology

Date 2014 Feb 4

PMID 24488080

Citations 18

Authors

Bess Dawson-Hughes

Susan S Harris

Lisa Ceglia

Nancy J Palermo

Affiliations

Soon will be listed here.

Abstract

Objective: Serum sclerostin levels have been reported to be inversely associated with serum 25OHD levels, but the effect of vitamin D and calcium supplementation on serum sclerostin levels is unknown. This study was carried out to determine whether vitamin D and calcium supplementation altered serum sclerostin levels in healthy older adults.

Design: We measured serum sclerostin levels at baseline and after 2 years in 279 men and women who participated in a placebo-controlled vitamin D (700 IU/day) and calcium (500 mg/day) intervention trial carried out in men and women aged ≥65 years.

Method: Serum sclerostin levels were measured using the MesoScale Discovery chemiluminescence assay.

Results: In the men, sclerostin levels increased over 2 years by 4.11±1.81 ng/l (13.1%) in the vitamin D plus calcium-supplemented group and decreased by 3.16±1.78 ng/l (10.9%) in the placebo group (P=0.005 for difference in change). Adjustments for the season of measurement, baseline physical activity levels, baseline serum sclerostin levels, and total body bone mineral content did not substantially alter the changes. In the women, there was no significant group difference in change in serum sclerostin levels either before or after the above-mentioned adjustments. In both the sexes, vitamin D and calcium supplementation significantly increased serum ionized calcium levels and decreased parathyroid hormone levels.

Conclusion: Men and women appear to have different serum sclerostin responses to vitamin D and calcium supplementation. The reason for this difference remains to be determined.

Citing Articles

Sclerostin: clinical insights in muscle-bone crosstalk.

Moretti A, Iolascon G J Int Med Res. 2023; 51(8):3000605231193293.

PMID: 37632438 PMC: 10467411. DOI: 10.1177/03000605231193293.

Serum sclerostin levels in osteoporotic fracture patients.

Gorter E, Reinders C, Krijnen P, Appelman-Dijkstra N, Schipper I Eur J Trauma Emerg Surg. 2022; 48(6):4857-4865.

PMID: 35705746 PMC: 9712313. DOI: 10.1007/s00068-022-02017-7.

Menopausal Transition: Prospective Study of Estrogen Status, Circulating MicroRNAs, and Biomarkers of Bone Metabolism.

Baloun J, Pekacova A, Wenchich L, Hruskova H, Senolt L, Svec X Front Endocrinol (Lausanne). 2022; 13:864299.

PMID: 35634507 PMC: 9137039. DOI: 10.3389/fendo.2022.864299.

Vitamin D Supplementation for 12 Months in Older Adults Alters Regulators of Bone Metabolism but Does Not Change Wnt Signaling Pathway Markers.

Christodoulou M, Aspray T, Piec I, Washbourne C, Tang J, Fraser W JBMR Plus. 2022; 6(5):e10619.

PMID: 35509637 PMC: 9059470. DOI: 10.1002/jbm4.10619.

Serum calcium and 25-hydroxyvitamin D in relation to longevity, cardiovascular disease and cancer: a Mendelian randomization study.

Yuan S, Baron J, Michaelsson K, Larsson S NPJ Genom Med. 2021; 6(1):86.

PMID: 34650087 PMC: 8516873. DOI: 10.1038/s41525-021-00250-4.

References

Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat R . Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2012; 24(2):489-94. DOI: 10.1007/s00198-012-1978-x. View

Modder U, Hoey K, Amin S, McCready L, Achenbach S, Riggs B . Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2010; 26(2):373-9. PMC: 3179347. DOI: 10.1002/jbmr.217. View

Fazeli P, E Ackerman K, Pierce L, Guereca G, Bouxsein M, Misra M . Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes. Osteoporos Int. 2013; 24(9):2433-40. PMC: 3740025. DOI: 10.1007/s00198-013-2353-2. View

Szulc P, Bertholon C, Borel O, Marchand F, Chapurlat R . Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2012; 28(4):855-64. DOI: 10.1002/jbmr.1823. View

Washburn R, Smith K, Jette A, Janney C . The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993; 46(2):153-62. DOI: 10.1016/0895-4356(93)90053-4. View

Krishnan V, Bryant H, MacDougald O . Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-9. PMC: 1451219. DOI: 10.1172/JCI28551. View

Preece M, ORIORDAN J, LAWSON D, KODICEK E . A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta. 1974; 54(2):235-42. DOI: 10.1016/0009-8981(74)90241-1. View

Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo J . Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2011; 97(1):234-41. DOI: 10.1210/jc.2011-2186. View

Bellido T, Ali A, Gubrij I, Plotkin L, Fu Q, OBrien C . Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146(11):4577-83. DOI: 10.1210/en.2005-0239. View

10.

Fuleihan G, Gundberg C, GLEASON R, Brown E, Stromski M, Grant F . Racial differences in parathyroid hormone dynamics. J Clin Endocrinol Metab. 1994; 79(6):1642-7. DOI: 10.1210/jcem.79.6.7989469. View

11.

Drake M, Srinivasan B, Modder U, Peterson J, McCready L, Riggs B . Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010; 95(11):5056-62. PMC: 2968729. DOI: 10.1210/jc.2010-0720. View

12.

Arasu A, Cawthon P, Lui L, Do T, Arora P, Cauley J . Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab. 2012; 97(6):2027-32. PMC: 3387417. DOI: 10.1210/jc.2011-3419. View

13.

Ardawi M, Al-Kadi H, Rouzi A, Qari M . Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res. 2011; 26(12):2812-22. DOI: 10.1002/jbmr.479. View

14.

Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini M . Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(5):1737-44. DOI: 10.1210/jc.2011-2958. View

15.

Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R . Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab. 2013; 98(9):3873-83. DOI: 10.1210/jc.2013-2113. View

16.

White J, Harris S, Dallal G, Dawson-Hughes B . Precision of single vs bilateral hip bone mineral density scans. J Clin Densitom. 2003; 6(2):159-62. DOI: 10.1385/jcd:6:2:159. View

17.

Dawson-Hughes B, Harris S, Krall E, Dallal G . Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997; 337(10):670-6. DOI: 10.1056/NEJM199709043371003. View

18.

Dawson-Hughes B, Harris S, Ceglia L, Palermo N . Serum sclerostin levels vary with season. J Clin Endocrinol Metab. 2013; 99(1):E149-52. PMC: 3879665. DOI: 10.1210/jc.2013-3148. View